Astrid L Voskamp

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Cell Cycle Arrest

Transcription Factor

Allergic Rhinitis

Chronic Rhinosinusitis

Top Venues

The Journal of experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Astrid L Voskamp, Nicolette W de Jong, Simon P Jochems, Arifa Ozir-Fazalalikhan, Oscar R J van Hengel, Luciën E P M van der Vlugt, Koen Alexander Stam, Maarten van den Berge, Martijn C Nawijn, Gerrit Johannes Braunstahl, Gertrude M Möller, Roy Gerth van Wijk, Hermelijn H Smits
Early expansion of allergen-responsive LAP + B regulatory cells in allergic rhinitis but not in allergic asthma subjects during allergen immunotherapy. Allergy 79 (4) (2024)
Astrid L Voskamp, Nicolette W de Jong, Simon P Jochems, Arifa Ozir-Fazalalikhan, Oscar R J van Hengel, Luciën E P M van der Vlugt, Koen Alexander Stam, Maarten van den Berge, Martijn C Nawijn, Gerrit Johannes Braunstahl, Gertrude M Möller, Roy Gerth van Wijk, Hermelijn H Smits
Early expansion of allergen-responsive LAP + B regulatory cells in allergic rhinitis but not in allergic asthma subjects during allergen immunotherapy. Allergy 79 (4) (2024)
Astrid L Voskamp, Nicolette W de Jong, Simon P Jochems, Arifa Ozir-Fazalalikhan, Oscar R J van Hengel, Luciën E P M van der Vlugt, Koen Alexander Stam, Maarten van den Berge, Martijn C Nawijn, Gerrit Johannes Braunstahl, Gertrude M Möller, Roy Gerth van Wijk, Hermelijn H Smits
Early expansion of allergen-responsive LAP + B regulatory cells in allergic rhinitis but not in allergic asthma subjects during allergen immunotherapy. Allergy (2024)
Astrid L Voskamp, Nicolette W de Jong, Simon P Jochems, Arifa Ozir-Fazalalikhan, Oscar R J van Hengel, Luciën E P M van der Vlugt, Koen Alexander Stam, Maarten van den Berge, Martijn C Nawijn, Gerrit Johannes Braunstahl, Gertrude M Möller, Roy Gerth van Wijk, Hermelijn H Smits
Early expansion of allergen-responsive LAP + B regulatory cells in allergic rhinitis but not in allergic asthma subjects during allergen immunotherapy. Allergy 79 (4) (2024)
Astrid L Voskamp, Sugandhika Khosa, Tracy Phan, Hannah A DeBerg, Judy Bingham, Mark Hew, William B Smith, Jodie Abramovitch, Jennifer M Rolland, Matthew Moyle, Kari Christine Nadeau, Gideon Lack, Mark Larché, Erik R Wambre, Robyn Elizabeth O'Hehir, Pascal L C Hickey, Sara R Prickett
Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy 79 (2) (2023)
Astrid L Voskamp, Sugandhika Khosa, Tracy Phan, Hannah A DeBerg, Judy Bingham, Mark Hew, William B Smith, Jodie Abramovitch, Jennifer M Rolland, Matthew Moyle, Kari Christine Nadeau, Gideon Lack, Mark Larché, Erik R Wambre, Robyn Elizabeth O'Hehir, Pascal L C Hickey, Sara R Prickett
Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy (2023)
Astrid L Voskamp, Tamar Tak, Maarten L Gerdes, Roberta Menafra, Ellen Duijster, Szymon M Kiełbasa, Tom Groot Kormelink, Koen Alexander Stam, Oscar R J van Hengel, Nicolette W de Jong, Rudi W Hendriks, Susan L Kloet, Maria M Yazdanbakhsh, Esther C De Jong, Roy Gerth van Wijk, Hermelijn H Smits
Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge. The Journal of experimental medicine 220 (9) (2023)
Astrid L Voskamp, Sugandhika Khosa, Tracy Phan, Hannah A DeBerg, Judy Bingham, Mark Hew, William B Smith, Jodie Abramovitch, Jennifer M Rolland, Matthew Moyle, Kari Christine Nadeau, Gideon Lack, Mark Larché, Erik R Wambre, Robyn Elizabeth O'Hehir, Pascal L C Hickey, Sara R Prickett
Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy 79 (2) (2023)
Astrid L Voskamp, Sugandhika Khosa, Tracy Phan, Hannah A DeBerg, Judy Bingham, Mark Hew, William B Smith, Jodie Abramovitch, Jennifer M Rolland, Matthew Moyle, Kari Christine Nadeau, Gideon Lack, Mark Larché, Erik R Wambre, Robyn Elizabeth O'Hehir, Pascal L C Hickey, Sara R Prickett
Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy 79 (2) (2023)